Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
Study sponsor: Prokidney
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-05-20Actual
Enrollment · participants53Actual
Source updated2026-03-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.